JoeSmartTrader

Day trading | Stocks Trading | ETFS

[Hated Moats Investor @HatedMoats]

🚨 Novo News in China 🇨🇳

The GLP-1 war just opened a dangerous new front. A Chinese drugmaker, armed with a molecule from Eli Lilly, is claiming its drug is superior to Novo Nordisk's blockbuster, with a direct shot at Novo's dominance in the world's second-largest market.

What Happened

On Monday, China's Innovent Biologics announced that its GLP-1 drug, mazdutide, demonstrated superior weight loss and blood sugar control compared to Novo Nordisk's ( $NVO) semaglutide (the active ingredient in Ozempic) in a late-stage, head-to-head trial.
The study in patients with type 2 diabetes and obesity showed a mean weight loss of 10.29% for patients on a 6 mg dose of mazdutide, versus 6% for those on a standard 1 mg dose of semaglutide.

Critically, Innovent licensed the rights to develop and sell mazdutide in China from none other than Novo's arch-rival, Eli Lilly ( $LLY).

My Take

This isn't that much about a surprise new competitor rather than a story about a proxy war. Eli Lilly has effectively armed a local champion to wage battle against Novo Nordisk on its behalf in the important Chinese market.

However, it's crucial to look past the headline numbers. The study compared Innovent’s 6 mg dose of mazdutide (a dual GLP-1/glucagon receptor agonist) against Novo’s 1 mg dose of semaglutide, which is a single-pathway GLP-1 agonist. That’s not an apples-to-apples comparison... at all. Higher doses of semaglutide (2.0 mg Ozempic or 2.4 mg Wegovy) have shown substantially greater efficacy, yet weren't included. Moreover, the open-label design, short 32-week duration, and exclusively Chinese study population all limit the generalisability of the results. It’s a clever, headline-friendly setup for noise but methodologically skewed in favour of the home team.

Regardless of these nuances, the strategic implication is clear. China will not be a simple duopoly for Western pharma giants. It’s shaping up to be a complex, multi-front battleground where strong domestic players will increasingly challenge Novo and Lilly, thus forcing price pressure, margin compression, and a new phase of competitive realism in the GLP-1 market.

Verdict: A Strategic Headwind

While the clinical "superiority" claim is very much debatable due to the mentioned methodological bias and disparity in the trial, the headline itself is a clear negative for Novo Nordisk. This development confirms that the competitive landscape in China is heating up dramatically, with its primary global rival using a local partner to attack its market share. This is a significant strategic headwind that complicates Novo's growth story in a key region.

What are your thoughts on this news?

[TacticzHazel @TacticzH]

$NVO could do 50%+ just from re-rating back to the median.

When we get some sector rotation (if it happens at all), I believe Novo will be a beneficiary.

[The Wall Street Journal @WSJ]

Anybody who has remodeled a home knows that building regulations can slow down even the most minor projects. Yet President Trump managed to tear down the East Wing of the White House with little notice in just a few days.

How did he do it? 🔗 https://t.co/tk8yjj8f8S

[JoeSmartTrader @JosephcoleT]

@WayneCallanJMB The kind of infrastructure we should’ve had years ago. Great to see it in action.

[Brett Adcock @adcock_brett]

Here’s an incredible photo from Time Magazine of our F.03 robot autonomously running dishes 🖤

[Deep Value Investing @DeepIceValue]

J.P. Morgan $JPM analyst Richard Vosser maintained a Buy rating on Novo Nordisk $NVO in a report released on October 17, setting a price target of DKK500.

[Michael Saylor @saylor]

₿uilt for this.

[The Economist @TheEconomist]

Taiwan’s primary aim is to convince Donald Trump to sustain America’s commitment to the island. But officials are also starting to hedge against the risk that he makes a strategic “grand bargain” with Xi Jinping at its expense https://t.co/IOGKl3YcPr

Photo: Getty Images

[JoeSmartTrader @JosephcoleT]

@WayneCallanJMB Policy means nothing without execution. Glad to see it handled.

[JoeSmartTrader @JosephcoleT]

@CallanJMBInc Finally, a company proving green can mean strong.Keep it up

[sugaray @1sugaray]

Missouri state

[Pete Thamel @PeteThamel]

Sources: Missouri State QB Jacob Clark is expected to return tonight at New Mexico State. He’s been out since suffering a lower body injury against Western Kentucky on Sept. 27. Barring a setback in pre-game, he’s set to start.

[AI at AMD @AIatAMD]

Overheard at AMD AI Dev Day... coding at dawn or coding at midnight? 🤔

We asked @danielhanchen, CEO @UnslothAI to pick sides in a lightning round.

#AMDevs #OpenSourceAIWeek

[Dr Singularity @Dr_Singularity]

2026 - The age of robots begins

[TacticzHazel @TacticzH]

$NVO - Novo Nordisk announces an Extraordinary General Meeting to elect new members of the Board of Directors.

The Chair (Helge Lund), Vice Chair (Henrik Poulsen), and five independent board members will not stand for re-election at this EGM. This effectively means a significant portion of the current board is stepping down.

It also suggests the Foundation is moving to install a Board that aligns more closely with its own vision for the company's future.

The Board of Directors supervises the performance of Novo Nordisk, its management and organization on behalf of the shareholders. It also participates in determining the company strategy, so they do have a critical role in the organization.

The new Board will be elected on November 14, 2025.

The change could potentially lead to shifts in long-term strategy.

[Lukas Ziegler @lukas_m_ziegler]

This robot will mark your floor! ✏️

The HP SitePrint printer delivers digital data directly to construction sites, increasing productivity by marking blueprints accurately.

The device is designed to be autonomous and to avoid obstacles, as well as to integrate seamlessly with Leica Geosystems part of Hexagon robotic total stations.

It has been tested in various projects and has proved to be a powerful tool for streamlining layout processes, reducing human error, and enabling customers such as Skanska to complete layouts faster, allowing senior operators to focus on quality control and other critical tasks. 🚧

[JoeSmartTrader @JosephcoleT]

@WayneCallanJMB It’s inspiring to see this mindset spreading

[JoeSmartTrader @JosephcoleT]

@CallanJMBInc I remember seeing a team scramble during a flood with no backup plan. Watching this mindset in action is the opposite—calm, ready, effective.

[Lukas Ziegler @lukas_m_ziegler]

This drone becomes a flying manipulator! 🥏

Researchers at the The University of Tokyo developed this aerial robot.

Built with four pairs of ducted fans linked by actuated joints, Dragon can reshape itself mid-flight.

This allows it to grasp objects and perform tasks typically reserved for ground-based manipulators. Each segment has dual rotors, and its navigation stack calculates the most efficient shape for each object.

Total payload? More than 3 kilograms.

P.S. To increase Dragon's battery life, they consider allowing it to walk on the ground.

[TacticzHazel @TacticzH]

$NVO = Undervalued. Have a nice weekend. NFA.